MCID: PLS025
MIFTS: 53

Plasmablastic Lymphoma

Categories: Rare diseases, Blood diseases, Immune diseases

Aliases & Classifications for Plasmablastic Lymphoma

MalaCards integrated aliases for Plasmablastic Lymphoma:

Name: Plasmablastic Lymphoma 53 59 73
Immunoblastic Large-Cell Lymphoma 73
Pbl 59

Classifications:



External Ids:

Orphanet 59 ORPHA289666
ICD10 via Orphanet 34 C83.3
UMLS via Orphanet 74 C3472614

Summaries for Plasmablastic Lymphoma

NIH Rare Diseases : 53 Plasmablastic lymphoma is an aggressive form of non-Hodgkin lymphoma. Although the condition most commonly occurs in the oral cavity, it can be diagnosed in many other parts of the body such as the gastrointestinal tract, lymph nodes, and skin. The exact underlying cause of plasmablastic lymphoma is poorly understood; however, it is often associated with suppression of the immune system (i.e. HIV infection, immunosuppressive therapy). There is currently no standard therapy for plasmablastic lymphoma. Treatment usually consists of chemotherapy with or without radiation therapy and hematopoietic stem cell transplantation.

MalaCards based summary : Plasmablastic Lymphoma, also known as immunoblastic large-cell lymphoma, is related to diffuse large b-cell lymphoma and primary effusion lymphoma. An important gene associated with Plasmablastic Lymphoma is MYC (MYC Proto-Oncogene, BHLH Transcription Factor), and among its related pathways/superpathways are Gastric cancer and Notch signaling pathway (KEGG). The drugs Lenograstim and Thiotepa have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and b cells, and related phenotypes are Reduced mammosphere formation and cellular

Wikipedia : 76 Plasmablastic lymphoma is a type of large B-cell lymphoma, recognized in the WHO 2008... more...

Related Diseases for Plasmablastic Lymphoma

Diseases related to Plasmablastic Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 134)
# Related Disease Score Top Affiliating Genes
1 diffuse large b-cell lymphoma 30.8 BCL6 MYC PRDM1
2 primary effusion lymphoma 30.5 BCL6 MYC
3 follicular lymphoma 30.2 BCL6 MS4A1 MYC
4 acquired immunodeficiency syndrome 30.0 BCL6 CD38 MYC
5 plasmacytoma 30.0 CD38 MYC PTPRC
6 burkitt lymphoma 29.6 BCL6 MS4A1 MYC
7 richter's syndrome 29.4 CD38 MYC NOTCH1
8 mantle cell lymphoma 29.4 BCL6 CDKN2A MTOR MYC
9 b-cell lymphomas 29.3 BCL6 CDKN2A MS4A1 MYC PRDM1
10 leukemia, chronic lymphocytic 28.4 ABCB1 BCL6 CD38 MS4A1 NOTCH1
11 caspase 8 deficiency 11.0
12 lymphoma 11.0
13 high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement 10.9 BCL6 MYC
14 heart lymphoma 10.8 BCL6 PTPRC
15 nodular lymphocyte predominant hodgkin lymphoma 10.8 BCL6 PTPRC
16 primary cutaneous anaplastic large cell lymphoma 10.8 MUC1 PTPRC
17 testicular lymphoma 10.8 BCL6 PTPRC
18 ovarian lymphoma 10.8 MYC PTPRC
19 hepatic angiomyolipoma 10.8 MTOR MYC
20 histiocytic sarcoma 10.7 MS4A1 MUC1
21 adult lymphoma 10.7 MYC PRDM1
22 hemimegalencephaly 10.7 MTOR MYC
23 mucinous cystadenocarcinoma 10.6 MUC1 PTPRC
24 epidural neoplasm 10.5 BCL6 PTPRC
25 malignant peritoneal mesothelioma 10.5 CDKN2A MUC1
26 lymphosarcoma 10.5 BCL6 PTPRC
27 lymphatic system cancer 10.5 BCL6 MYC PTPRC
28 mucinous bronchioloalveolar adenocarcinoma 10.5 CDKN2A MUC1
29 endometrial mucinous adenocarcinoma 10.5 CDKN2A MUC1
30 reticulosarcoma 10.5 BCL6 MUC1 PTPRC
31 vulvar seborrheic keratosis 10.5 CDKN2A MTOR
32 sarcomatoid mesothelioma 10.5 CDKN2A MUC1
33 megaesophagus 10.5 CDKN2A MYC
34 primary central nervous system lymphoma 10.4 BCL6 CDKN2A
35 bartholin's gland benign neoplasm 10.4 CDKN2A MTOR
36 well-differentiated liposarcoma 10.4 CDKN2A MUC1
37 multicentric castleman disease 10.4 ABCB1 BCL6
38 suppressor of tumorigenicity 3 10.4 CDKN2A MYC
39 cell type cancer 10.3 CDKN2A MUC1 MYC
40 colon lymphoma 10.2 BCL6 CDKN2A PTPRC
41 lymphoblastic lymphoma 10.2 BCL6 NOTCH1 PTPRC
42 cutaneous leiomyosarcoma 10.2 DES MUC1
43 spindle cell thymoma 10.2 DES MUC1
44 central nervous system lymphoma 10.2 BCL6 CDKN2A PRDM1
45 bone squamous cell carcinoma 10.2 CDKN2A NOTCH1
46 parachordoma 10.2 DES MUC1
47 ossifying fibromyxoid tumor 10.2 DES MUC1
48 primitive neuroectodermal tumor of the cervix uteri 10.2 DES PTPRC
49 syringocystadenoma papilliferum 10.1 DES MUC1
50 spindle cell rhabdomyosarcoma 10.1 DES MUC1

Graphical network of the top 20 diseases related to Plasmablastic Lymphoma:



Diseases related to Plasmablastic Lymphoma

Symptoms & Phenotypes for Plasmablastic Lymphoma

GenomeRNAi Phenotypes related to Plasmablastic Lymphoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.1 BCL6 DES MTOR MYC NOTCH1 PTPRC

MGI Mouse Phenotypes related to Plasmablastic Lymphoma:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.21 MYC PTPRC NOTCH1 VDR PRDM1 DES
2 cardiovascular system MP:0005385 10.18 MYC NOTCH1 VDR PRDM1 DES BCL6
3 endocrine/exocrine gland MP:0005379 10.18 PTPRC NOTCH1 VDR PRDM1 MYC BCL6
4 hematopoietic system MP:0005397 10.17 PTPRC NOTCH1 VDR PRDM1 MYC BCL6
5 homeostasis/metabolism MP:0005376 10.14 MYC PTPRC NOTCH1 VDR PRDM1 DES
6 growth/size/body region MP:0005378 10.11 PRDM1 MYC PTPRC NOTCH1 VDR CDKN2A
7 immune system MP:0005387 10.11 PTPRC NOTCH1 VDR PRDM1 MYC BCL6
8 digestive/alimentary MP:0005381 9.97 MYC PTPRC NOTCH1 VDR CDKN2A ABCB1
9 mortality/aging MP:0010768 9.96 PRDM1 MYC PTPRC NOTCH1 VDR CDKN2A
10 liver/biliary system MP:0005370 9.87 PRDM1 MYC PTPRC NOTCH1 BCL6 CDKN2A
11 muscle MP:0005369 9.76 MYC NOTCH1 VDR PRDM1 DES BCL6
12 neoplasm MP:0002006 9.35 PRDM1 MYC PTPRC NOTCH1 CDKN2A
13 no phenotypic analysis MP:0003012 9.17 PRDM1 MYC PTPRC ABCB1 BCL6 MTOR

Drugs & Therapeutics for Plasmablastic Lymphoma

Drugs for Plasmablastic Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 452)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
2
Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 52-24-4 5453
3
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
4 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
5 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
6 Antilymphocyte Serum Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
7 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
8 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
9
rituximab Approved Phase 3,Phase 1,Phase 2,Not Applicable 174722-31-7 10201696
10
Fludarabine Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 21679-14-1, 75607-67-9 30751
11
Etoposide Approved Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 33419-42-0 36462
12
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
13
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
14
Ciprofloxacin Approved, Investigational Phase 3,Not Applicable 85721-33-1 2764
15
Carboplatin Approved Phase 2, Phase 3,Phase 1,Not Applicable 41575-94-4 10339178 498142 38904
16
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
17
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
18
Cefepime Approved, Investigational Phase 3,Phase 1 88040-23-7 5479537
19
Methotrexate Approved Phase 3,Phase 2,Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
20
Ofloxacin Approved Phase 3 82419-36-1 4583
21
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 147-94-4 6253
22
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
23
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
24
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 55-98-1 2478
25
Idarubicin Approved Phase 3 58957-92-9 42890
26
Prednisolone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
27
Amoxicillin Approved, Vet_approved Phase 3,Not Applicable 26787-78-0 33613
28
Melphalan Approved Phase 3,Phase 2,Phase 1,Not Applicable 148-82-3 4053 460612
29
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1,Not Applicable 24280-93-1 446541
30
Mitoxantrone Approved, Investigational Phase 3,Phase 1,Phase 2 65271-80-9 4212
31
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 128794-94-5 5281078
32
Bleomycin Approved, Investigational Phase 3,Phase 1,Phase 2 11056-06-7 5360373
33
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
34
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
35
Carmustine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 154-93-8 2578
36
Prednisone Approved, Vet_approved Phase 3,Phase 2,Phase 1 53-03-2 5865
37
Tazobactam Approved Phase 3 89786-04-9 123630
38
Hydrocortisone Approved, Vet_approved Phase 3,Phase 2,Phase 1 50-23-7 5754
39
Ribavirin Approved Phase 3 36791-04-5 37542
40
Captopril Approved Phase 3 62571-86-2 44093
41
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 51-75-2 4033
42
Heparin Approved, Investigational Phase 3,Not Applicable 9005-49-6 772 46507594
43
Iron Approved Phase 3,Phase 2,Phase 1,Not Applicable 7439-89-6 23925
44
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
45
Ephedrine Approved Phase 3 299-42-3 9294
46
Mesna Approved, Investigational Phase 3,Phase 1,Phase 2 3375-50-6 598
47
Pseudoephedrine Approved Phase 3 90-82-4 7028
48
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
49
Morphine Approved, Investigational Phase 3,Not Applicable 57-27-2 5288826
50
Iodine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 7553-56-2 807

Interventional clinical trials:

(show top 50) (show all 544)
# Name Status NCT ID Phase Drugs
1 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
2 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
3 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
4 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
5 Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
6 Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
7 Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
8 Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00003815 Phase 3 carmustine;cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;melphalan;prednisolone;vincristine sulfate
9 Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00053768 Phase 3 EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
10 High Dose Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma Unknown status NCT00003578 Phase 3 CHOP regimen;carmustine;cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;melphalan;prednisone;vincristine sulfate
11 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
12 Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma Completed NCT00002565 Phase 3 CHOP regimen;cisplatin;cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;idarubicin;ifosfamide;mesna;methylprednisolone;mitoxantrone hydrochloride;prednisone;vincristine sulfate
13 Combination Chemotherapy in Treating Patients With Lymphoma Completed NCT00002835 Phase 3 Carmustine;Cisplatin (CDDP);Cyclophosphamide;Cytarabine (ARA-C);Etoposide (VP-16);Idarubicin;Ifosfamide;Leucovorin Calcium;Melphalan;Methotrexate;Methylprednisolone;mitoxantrone hydrochloride (DHAD);Vincristine Sulfate
14 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
15 Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma Completed NCT00002649 Phase 3 cyclophosphamide;etoposide
16 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
17 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
18 Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Previously Untreated HIV-Associated Non-Hodgkin's Lymphoma Completed NCT00003595 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
19 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
20 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
21 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
22 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
23 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
24 Combination Chemotherapy in Treating Older Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma Completed NCT00002576 Phase 3 cyclophosphamide;doxorubicin hydrochloride;mitoxantrone hydrochloride;prednisolone;vincristine sulfate
25 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
26 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
27 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
28 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3 levofloxacin
29 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
30 Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Older Patients With Non-Hodgkin's Lymphoma Completed NCT00003150 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
31 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma Completed NCT00003215 Phase 3 CHOP regimen;cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;leucovorin calcium;melphalan;methotrexate;methylprednisolone;mitoxantrone hydrochloride;prednisone;therapeutic hydrocortisone;vincristine sulfate
32 Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy Completed NCT00003341 Phase 3
33 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
34 Combination Chemotherapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma Completed NCT00005867 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;mitoxantrone hydrochloride;prednisolone;vincristine sulfate
35 Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma Completed NCT00278421 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
36 Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma Completed NCT00278408 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
37 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
38 Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Completed NCT00014391 Phase 3 ribavirin
39 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3 fluconazole;itraconazole
40 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
41 SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma Completed NCT00004031 Phase 3 CHOP regimen;carmustine;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
42 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
43 Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer Completed NCT00265837 Phase 3
44 Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer Completed NCT00053053 Phase 3
45 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
46 Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
47 Combination Chemotherapy in Treating Pediatric Patients With Advanced-Stage Large Cell Lymphoma Completed NCT00002618 Phase 3 cytarabine;doxorubicin hydrochloride;leucovorin calcium;mercaptopurine;methotrexate;prednisone;vincristine sulfate
48 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
49 Rituxan vs Bexxar When Combined With Carmustine, Etoposide, Cytarabine and Melphalan (BEAM) With Autologous Hematopoietic Stem Cell Transplantation (BMT CTN 0401) Completed NCT00329030 Phase 3 Autologous transplantation using rituxan/BEAM;Autologous transplantation using Bexxar/BEAM
50 Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer Completed NCT00369564 Phase 3 glutamic acid

Search NIH Clinical Center for Plasmablastic Lymphoma

Genetic Tests for Plasmablastic Lymphoma

Anatomical Context for Plasmablastic Lymphoma

MalaCards organs/tissues related to Plasmablastic Lymphoma:

41
Bone, Bone Marrow, B Cells, T Cells, Liver, Kidney, Lymph Node

Publications for Plasmablastic Lymphoma

Articles related to Plasmablastic Lymphoma:

(show top 50) (show all 314)
# Title Authors Year
1
Plasmablastic lymphoma presenting as a ureteral polypoid mass. ( 29692511 )
2018
2
Post-treatment positron emission tomography-computed tomography is highly predictive of outcome in Plasmablastic lymphoma. ( 29679112 )
2018
3
Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis. ( 29303024 )
2018
4
SLAMF7 (CD319/CS1) is expressed in plasmablastic lymphoma and is a potential diagnostic marker and therapeutic target. ( 29785767 )
2018
5
Dual Threat of Epstein-Barr Virus: an Autopsy Case Report of HIV-Positive Plasmablastic Lymphoma Complicating EBV-Associated Hemophagocytic Lymphohistiocytosis. ( 29687211 )
2018
6
Successful Use of Bortezomib-Lenalidomide Combination as Treatment for a Patient With Plasmablastic Lymphoma. ( 29753690 )
2018
7
A patient with plasmablastic lymphoma achieving long-term complete remission after thalidomide-dexamethasone induction and double autologous stem cell transplantation: a case report. ( 29879938 )
2018
8
Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma. ( 29527667 )
2018
9
First Occurrence of Plasmablastic Lymphoma in Adenosine Deaminase-Deficient Severe Combined Immunodeficiency Disease Patient and Review of the Literature. ( 29456531 )
2018
10
Clinicopathological analysis of oral plasmablastic lymphoma: A systematic review. ( 29917262 )
2018
11
Orbital plasmablastic lymphoma. ( 29375870 )
2018
12
Plasmablastic lymphoma: Review of 60 Chinese cases and prognosis analysis. ( 28248855 )
2017
13
Plasmablastic Lymphoma with Coexistence of Chronic Lymphocytic Leukemia in an Immunocompetent Patient: A Case Report and Mini-Review. ( 29387498 )
2017
14
Plasmablastic Lymphoma. ( 28746329 )
2017
15
Plasmablastic lymphoma versus plasmablastic myeloma: an ongoing diagnostic dilemma. ( 28249941 )
2017
16
Plasmablastic Lymphoma in a Patient With Crohn's Disease After Extensive Immunosuppressive Therapy. ( 28782668 )
2017
17
Bortezomib in plasmablastic lymphoma: A glimpse of hope for a hard-to-treat disease. ( 28963907 )
2017
18
Oral plasmablastic lymphoma as the first manifestation of AIDS. ( 29267464 )
2017
19
Durable remission is achievable with localized treatment and reduction of immunosuppression in limited stage EBV-related plasmablastic lymphoma. ( 28831541 )
2017
20
A case of HIV-negative plasmablastic lymphoma of the bone marrow with a unique immunophenotype. ( 28588836 )
2017
21
Long-Term Survival of Primary Intracranial Plasmablastic Lymphoma: Case Report and Review of the Literature. ( 27794513 )
2017
22
Interleukin-6-dependent growth in a newly established plasmablastic lymphoma cell line and its therapeutic targets. ( 28860565 )
2017
23
Intraocular Plasmablastic Lymphoma in a HIV Patient. ( 28929004 )
2017
24
Unusual presentation of plasmablastic lymphoma involving ovarian mature cystic teratoma: a case report. ( 29187222 )
2017
25
Plasmablastic lymphoma with unfavorable chromosomal abnormalities related to plasma cell myeloma: A borderline case between plasmablastic lymphoma and plasmablastic plasma cell myeloma ( 28679965 )
2017
26
Durable complete remission with combination chemotherapy and bortezomib in HIV-associated plasmablastic lymphoma. ( 28993364 )
2017
27
MicroRNAs sequencing unveils distinct molecular subgroups of plasmablastic lymphoma. ( 29296171 )
2017
28
Primary cutaneous plasmablastic lymphoma presenting as perineal ulcero-proliferative growth in a human immunodeficiency virus-seropositive patient. ( 27779143 )
2017
29
Primary cutaneous plasmablastic lymphoma in an immunocompetent patient: is it associated with an indolent course? ( 29081245 )
2017
30
Plasmablastic lymphoma phenotype is determined by genetic alterations in MYC and PRDM1. ( 27687004 )
2017
31
Plasmablastic lymphoma presenting as exophytic skin lesions. ( 28700895 )
2017
32
Plasmablastic Lymphoma: Case Report of Prolonged Survival of an Advanced Human Immunodeficiency Patient and Literature Review. ( 29090101 )
2017
33
Mediastinal syndrome from plasmablastic lymphoma in human immunodeficiency virus and human herpes virus 8 negative patient with polycythemia vera: a case report. ( 28320457 )
2017
34
Pediatric plasmablastic lymphoma: Diagnostic and therapeutic dilemma. ( 28631667 )
2017
35
A Case of Plasmablastic Lymphoma Achieving Complete Response and Durable Remission after Lenalidomide-Based Therapy. ( 28095384 )
2017
36
Successful cord blood transplantation for an HIV-negative patient with refractory plasmablastic lymphoma. ( 28293711 )
2017
37
Plasmablastic lymphoma in immunocompetent and in immunocompromised patients: Experience at a regional cancer centre in India. ( 28702410 )
2017
38
11C-Methionine-Avid Plasmablastic Lymphoma. ( 28825948 )
2017
39
HIV-negative plasmablastic lymphoma attaining sustained remission with bortezomib-combined dose-adjusted EPOCH therapy. ( 28592757 )
2017
40
Human immunodeficiency virus-negative plasmablastic lymphoma: A case report and literature review. ( 28207555 )
2017
41
Long-term remission in a case of plasmablastic lymphoma treated with COMP (cyclophosphamide, liposomal doxorubicin, vincristine, prednisone) and bortezomib. ( 26715026 )
2016
42
Solitary plasmablastic lymphoma in the esophagus. ( 26925582 )
2016
43
Refractory plasmablastic lymphoma-a review of treatment options beyond standard therapy. ( 28011983 )
2016
44
Plasmablastic lymphoma presenting as a large intracardiac mass and bilateral pleural effusions. ( 26607603 )
2016
45
Plasmablastic Lymphoma Mimicking Acute Pancreatitis. ( 27034868 )
2016
46
Human immunodeficiency virus associated plasmablastic lymphoma: A case report. ( 27795651 )
2016
47
Infusional dose-adjusted epoch plus bortezomib for the treatment of plasmablastic lymphoma. ( 26801792 )
2016
48
A rare presentation of plasmablastic lymphoma as cutaneous nodules in an immunocompromised patient. ( 27738277 )
2016
49
Primary testicular plasmablastic lymphoma: unique case in a 30 year old. ( 27121529 )
2016
50
Immune-checkpoint expression in Epstein-Barr virus positive and negative plasmablastic lymphoma: a clinical and pathological study in 82 patients. ( 27175027 )
2016

Variations for Plasmablastic Lymphoma

Expression for Plasmablastic Lymphoma

Search GEO for disease gene expression data for Plasmablastic Lymphoma.

Pathways for Plasmablastic Lymphoma

Pathways related to Plasmablastic Lymphoma according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.32 ABCB1 CDKN2A MTOR MYC NOTCH1
2
Show member pathways
12.27 BCL6 MTOR MYC NOTCH1
3 12.22 BCL6 CD38 PRDM1 PTPRC
4 11.96 CDKN2A MTOR MYC
5 11.85 BCL6 PRDM1 VDR
6 11.83 ABCB1 CDKN2A MTOR MYC NOTCH1
7 11.75 MTOR MYC NOTCH1
8 11.73 BCL6 CDKN2A MYC
9 11.71 BCL6 MUC1 MYC
10 11.68 CDKN2A MTOR MYC
11 11.52 CD38 MS4A1 NOTCH1 PTPRC
12 11.41 CD38 MS4A1 PTPRC
13
Show member pathways
11.36 CDKN2A MTOR PRDM1
14 10.92 CDKN2A MYC
15
Show member pathways
10.91 CDKN2A MYC
16 10.78 ABCB1 VDR
17 10.75 BCL6 CD38 MS4A1 PRDM1 PTPRC
18 10.71 ABCB1 VDR
19 10.7 ABCB1 MTOR

GO Terms for Plasmablastic Lymphoma

Cellular components related to Plasmablastic Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.36 BCL6 CD38 CDKN2A DES MS4A1 MTOR

Biological processes related to Plasmablastic Lymphoma according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription by RNA polymerase II GO:0000122 9.85 BCL6 MYC NOTCH1 PRDM1 VDR
2 negative regulation of cell proliferation GO:0008285 9.81 BCL6 CDKN2A NOTCH1 VDR
3 negative regulation of transcription, DNA-templated GO:0045892 9.65 BCL6 CD38 CDKN2A NOTCH1 VDR
4 negative regulation of cell-matrix adhesion GO:0001953 9.49 BCL6 CDKN2A
5 negative regulation of B cell proliferation GO:0030889 9.48 CDKN2A PRDM1
6 positive regulation of keratinocyte differentiation GO:0045618 9.43 NOTCH1 VDR
7 energy reserve metabolic process GO:0006112 9.4 MTOR MYC
8 positive regulation of glial cell proliferation GO:0060252 9.37 MTOR MYC
9 positive regulation of gene expression GO:0010628 9.35 CDKN2A MTOR MYC PRDM1 VDR
10 positive regulation of B cell proliferation GO:0030890 9.33 BCL6 CD38 PTPRC
11 somatic stem cell division GO:0048103 9.32 CDKN2A NOTCH1
12 cell cycle arrest GO:0007050 8.92 CDKN2A MTOR MYC NOTCH1

Molecular functions related to Plasmablastic Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 sequence-specific DNA binding GO:0043565 9.02 BCL6 MYC NOTCH1 PRDM1 VDR

Sources for Plasmablastic Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....